{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:53:15Z","timestamp":1793735595399,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Asciminib, the first BCR::ABL1 inhibitor that\n                    <jats:underline>S<\/jats:underline>\n                    pecifically\n                    <jats:underline>T<\/jats:underline>\n                    argets the\n                    <jats:underline>A<\/jats:underline>\n                    BL\n                    <jats:underline>M<\/jats:underline>\n                    yristoyl\n                    <jats:underline>P<\/jats:underline>\n                    ocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome\u2013positive chronic myeloid leukemia in chronic phase (CML-CP) treated with \u22652 prior tyrosine kinase inhibitors (TKIs). In ASCEMBL, patients with CML-CP treated with \u22652 prior TKIs were randomized (stratified by baseline major cytogenetic response [MCyR]) 2:1 to asciminib 40\u2009mg twice daily or bosutinib 500\u2009mg once daily. Consistent with previously published primary analysis results, after a median follow-up of 2.3 years, asciminib continued to demonstrate superior efficacy and better safety and tolerability than bosutinib. The major molecular response (MMR) rate at week 96 (key secondary endpoint) was 37.6% with asciminib vs 15.8% with bosutinib; the MMR rate difference between the arms, after adjusting for baseline MCyR, was 21.7% (95% CI, 10.53\u201332.95; two-sided\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001). Fewer grade \u22653 adverse events (AEs) (56.4% vs 68.4%) and AEs leading to treatment discontinuation (7.7% vs 26.3%) occurred with asciminib than with bosutinib. A higher proportion of patients on asciminib than bosutinib remained on treatment and continued to derive benefit over time, supporting asciminib as a standard of care for patients with CML-CP previously treated with \u22652 TKIs.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-01829-9","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T11:14:34Z","timestamp":1675077274000},"page":"617-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"R\u00e9a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Boquimpani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-1794","authenticated-orcid":false,"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elza","family":"Lomaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Voloshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-2371","authenticated-orcid":false,"given":"Anna","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Abdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Maria","family":"Fogliatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-5785","authenticated-orcid":false,"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeem","family":"Chaudhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4250-4448","authenticated-orcid":false,"given":"Lynette","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-0815","authenticated-orcid":false,"given":"Valentin","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Allepuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Quenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"B\u00e9doucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-4032","authenticated-orcid":false,"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"1829_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.","journal-title":"J Hematol Oncol"},{"key":"1829_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garcia-Gutierrez V, Rea D, Janssen J, et al. Expert opinion\u2014management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495\u2013502.","journal-title":"Leukemia."},{"key":"1829_CR3","unstructured":"Chronic Myeloid Leukemia, V1.2023, NCCN Clinical Practice Guidelines in Oncology."},{"key":"1829_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia."},{"key":"1829_CR5","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen J, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41\u2013iv51.","journal-title":"Ann Oncol"},{"key":"1829_CR6","first-page":"421","volume":"11","author":"LP Akard","year":"2013","unstructured":"Akard LP, Albitar M, Hill CE, Pinilla-Ibarz J. The \u201chit hard and hit early\u201d approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer Network clinical practice guidelines for routine practice. Clin Adv Hematol Oncol. 2013;11:421\u201332.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1829_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.htct.2018.11.005","volume":"41","author":"GR Bosi","year":"2019","unstructured":"Bosi GR, Fogliatto LM, Costa TEV, Grokoski KC, Pereira MP, Bugs N, et al. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials? Hematol Transfus Cell Ther. 2019;41:222\u20138.","journal-title":"Hematol Transfus Cell Ther"},{"key":"1829_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome\u2013positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12:39.","journal-title":"J Hematol Oncol"},{"key":"1829_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/ajh.24536","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol. 2016;91:1206\u201314.","journal-title":"Am J Hematol"},{"key":"1829_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood."},{"key":"1829_CR11","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"RJ Garg","year":"2009","unstructured":"Garg RJ, Kantarjian H, O\u2019Brien S, Quintas-Cardama A, Faderl S, Estrov Z, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114:4361\u20138.","journal-title":"Blood."},{"key":"1829_CR12","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648\u201371.","journal-title":"Leukemia."},{"key":"1829_CR13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D Rea","year":"2021","unstructured":"Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood."},{"key":"1829_CR14","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u201326.","journal-title":"N Engl J Med"},{"key":"1829_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2020-139677","volume":"136","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Hughes TP, Mauro M, Hochhaus A, Rea D, Goh YT, et al. Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 Trial. Blood. 2020;136:632. Abstract","journal-title":"Blood."},{"key":"1829_CR16","doi-asserted-by":"crossref","unstructured":"Hughes TP, Cortes JE, Rea D, Mauro M, Hochhaus A, Kim DW, et al. Asciminib provides durable molecular responses in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial. In: EHA2022 Hybrid Congress. Vienna, Austria; 2022. Abstract 4106.","DOI":"10.1097\/01.HS9.0000845700.84142.c0"},{"key":"1829_CR17","unstructured":"Scemblix (asciminib). Prescribing information. Novartis Pharmaceuticals Corp; 2021. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/scemblix.pdf. Accessed November 10, 2022."},{"key":"1829_CR18","doi-asserted-by":"crossref","unstructured":"Mauro M, Minami Y, Rea D, Hochhaus A, Lomaia E, Voloshin S, et al. Efficacy and safety results from Ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-classSTAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: update after 48 weeks. In: 63rd ASH Annual Meeting & Exposition. Atlanta, GA; 2021. Abstract 310.","DOI":"10.1182\/blood-2021-152561"},{"key":"1829_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood."},{"key":"1829_CR20","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.leukres.2008.12.017","volume":"33","author":"D Kim","year":"2009","unstructured":"Kim D, Kim DW, Cho BS, Goh HG, Kim SH, Kim WS, et al. Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations. Leuk Res. 2009;33:1260\u20135.","journal-title":"Leuk Res"},{"key":"1829_CR21","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41375-018-0055-7","volume":"32","author":"S Saussele","year":"2018","unstructured":"Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, et al. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia. 2018;32:1222\u20138.","journal-title":"Leukemia."},{"key":"1829_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia."},{"key":"1829_CR23","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"P Manley","year":"2020","unstructured":"Manley P, Barys L, Cowan-Jacob S. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458. Published online September 29, 2020","journal-title":"Leuk Res"},{"key":"1829_CR24","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1038\/s41375-020-01037-9","volume":"34","author":"H Zhao","year":"2020","unstructured":"Zhao H, Deininger MW. Declaration of Bcr-Abl1 independence. Leukemia. 2020;34:2827\u201336.","journal-title":"Leukemia."},{"key":"1829_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ctrv.2011.07.004","volume":"38","author":"G Rosti","year":"2012","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M. Physician\u2019s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev. 2012;38:241\u20138.","journal-title":"Cancer Treat Rev"},{"key":"1829_CR26","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012;53:2351\u201361.","journal-title":"Leuk Lymphoma"},{"key":"1829_CR27","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brummendorf TH, Smith BD, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125\u201337.","journal-title":"Leukemia."},{"key":"1829_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/hematology.2020006911","volume":"2020","author":"J Cortes","year":"2020","unstructured":"Cortes J. How to manage CML patients with comorbidities. Hematol Am Soc Hematol Educ Program. 2020;2020:237\u201342.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1829_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","volume":"2017","author":"MC Barber","year":"2017","unstructured":"Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematol Am Soc Hematol Educ Program. 2017;2017:110\u20134.","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01829-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01829-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01829-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T04:31:47Z","timestamp":1678163507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01829-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1829"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01829-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"6 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following potential conflicts of interest: AH received institutional research support from Novartis, Bristol Myers Squibb, Incyte, and Pfizer and personal fees from Novartis and Incyte. DR received personal fees from Novartis, Pfizer, and Incyte. CB received grants from Novartis during the conduct of the study. YM received honoraria from Bristol Myers Squibb, Novartis, Pfizer, and Astellas. JEC received grants and consulting fees from Novartis, grants and consulting fees from Pfizer, and grants from Bristol Myers Squibb. TPH received grants and honoraria for advisory boards and symposia from Novartis and grants from Bristol Myers Squibb. JFA received honoraria, grants, and personal fees from Novartis and grants and personal fees from Pfizer. EL received grants from Novartis and personal fees and non-financial support from Novartis, Pfizer, and Bristol Myers Squibb. SV received personal fees and non-financial support from Novartis, AbbVie, Janssen, Sanofi, and BIOCAD; non-financial support from Pfizer; and personal fees from Takeda and AstraZeneca. AT declares no competing financial interests. D-WK received grants from Novartis, Bristol Myers Squibb, Pfizer, ILYANG, and Takeda. AAbdo received honoraria from Novartis and Takeda. LMF declares no competing financial interests. PlC received speaker\u2019s honoraria from Novartis, Incyte, Pfizer, and Bristol Myers Squibb. KS received research funding and honoraria for advisory boards from Novartis. DDHK received grants, honoraria, and consulting fees from Novartis; grants from Bristol Myers Squibb; and honoraria from Pfizer and Paladin. SS received honoraria, grants, and personal fees from Novartis and grants and personal fees from Bristol Myers Squibb and Incyte, and honoraria from Roche and Pfizer. MA declares no competing financial interests. NC declares no competing financial interests. LC received honoraria and participated in advisory boards for Novartis and Otsuka. VG-G received grants, non-financial support, and honoraria from Novartis, Pfizer, Bristol Myers Squibb, and Incyte. SK is an employee of Novartis. AAllepuz is an employee of Novartis. SQ is an employee of Novartis. VB is an employee of Novartis. MJM received personal fees from Bristol Myers Squibb, Takeda, and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}